JP Delord, et al. ASCO 2022 Abstract available on the ASCO website – Download the poster here Poster Presentation
Category: Myvac
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
Transgene presented additional Phase I Data with TG4050 at ASCO 2022
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
Transgene to present updated positive preliminary data at ASCO 2022
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
MS Block et al. AACR 2022 Download the publication here
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
MS Block et al.AACR 2022Read the abstract here – Download the poster herePoster Presentation
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
Transgene to present new positive preliminary Phase I Clinical data
Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
Transgene to present new positive preliminary Phase I data on TG4050
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
20210302 – Transgene Scientific Conferences
First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
20210121 TG4050 1st patient HNSCC EN
